# Prelude Therapeutics

Source: https://onco.cc/companies/prelude-therapeutics/  
OnCo record `prelude-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prelude Therapeutics develops precision cancer medicines. Its current focus is a pill for blood cancers driven by a JAK2 mutation and drugs that destroy a protein called KAT6A in hormone-driven breast cancer.

## Summary

Prelude Therapeutics is a Wilmington, Delaware clinical-stage precision oncology company. Its pipeline page lists PR-01, a JAK2 V617F mutant-selective JH2 inhibitor in a phase 1 trial enrolling patients with V617F-positive myeloproliferative neoplasms (myelofibrosis, polycythaemia vera, essential thrombocythaemia); highly selective KAT6A degraders for ER-positive breast cancer, with phase 1 initiation anticipated in the fourth quarter of 2026; a mutant CALR-directed degrader antibody conjugate (DAC) for CALR-mutated MPNs; and degrader payloads for DACs offered for partnership. Earlier PRMT5 (PRT543, PRT811) and MCL1 programmes have been deprioritised. Prelude completed its Nasdaq IPO in September 2020, raising about 181.9 million US dollars gross.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Wilmington, DE
- Type: biotech
- Website: https://preludetx.com/
- Ticker: PRLD

## Notes

- Myeloproliferative neoplasms have no id in the cancer list. Founding year not sourced. The statement that earlier PRMT5 and MCL1 programmes were deprioritised is inferred from their absence on the current pipeline page.

## Sources

- Official website: https://preludetx.com/
- Pipeline: https://preludetx.com/science/pipeline/
- Q3 2020 results noting IPO (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1678660/000156459020052741/prld-ex991_6.htm

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Degrader-antibody conjugate (DAC)](https://onco.cc/technologies/degrader-antibody-conjugate/), [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)

---
JSON: https://onco.cc/api/v1/entities/prelude-therapeutics.json